A patient presents with a BMI of 38, newly diagnosed hypertension, and no personal or family history of medullary thyroid carcinoma. The clinical question — tirzepatide or semaglutide — previously required clinicians to triangulate across single-arm phase 3 datasets with different enrollment windows, different baseline BMIs, and different follow-up durations. SURMOUNT-5 changed that by placing both agents in a single randomized design with identical eligibility criteria, the same primary endpoint, and a 72-week treatment window — producing the first rigorously controlled head-to-head efficacy comparison in the peer-reviewed literature on tirzepatide vs semaglutide for weight loss.
SURMOUNT-5 Trial Design and Study Population
SURMOUNT-5 (NCT05822609) is a phase 3b, open-label, randomized controlled trial comparing tirzepatide (Mounjaro/Zepbound, Eli Lilly) to semaglutide 2.4 mg/week (Wegovy, Novo Nordisk) as once-weekly subcutaneous injections in adults with overweight or obesity without type 2 diabetes. The trial enrolled 751 participants, randomized 1:1 to tirzepatide (escalated to a maximum of 15 mg/week) or semaglutide (escalated to 2.4 mg/week per the approved Wegovy titration schedule). Results were published in The New England Journal of Medicine in 2025 (Jastreboff AM et al., NEJM 2025).
Enrollment required a BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity — including hypertension, dyslipidemia, obstructive sleep apnea, or established cardiovascular disease. Key exclusion criteria included a diagnosis of type 2 diabetes, personal or family history of medullary thyroid carcinoma or MEN2, and prior use of either study agent. Baseline mean body weight across both arms was approximately 113 kg, with a mean BMI of approximately 40 kg/m² — characterizing the enrolled population as class II–III obesity, broadly representative of the patient profiles presenting to metabolic medicine and endocrinology clinics.
The open-label design was necessitated by the inherently different injection volumes, autoinjector device formats, and titration intervals between the two agents; blinding would have required a sham injection protocol that was not employed. Randomization was stratified by baseline BMI category and geographic region. Both the primary endpoint and all prespecified secondary endpoints were centrally adjudicated using a modified intent-to-treat analysis framework.
Primary Endpoint: Tirzepatide vs Semaglutide Mean Body Weight Reduction at 72 Weeks
On the primary endpoint — percent change in body weight from baseline to week 72 — tirzepatide produced a mean reduction of 20.2%, compared to 13.7% for semaglutide. The estimated treatment difference of approximately 6.5 percentage points was statistically significant (p < 0.001; 95% CI approximately −7.9 to −5.1). In absolute weight terms, against a shared baseline of ~113 kg, this translated to a mean loss of approximately 22.8 kg for tirzepatide versus approximately 15.0 kg for semaglutide.
The magnitude of this between-group difference merits careful contextualization rather than simple dismissal or overstatement. A 6.5 percentage point separation on a mean weight-loss outcome in an RCT represents a clinically meaningful effect at the population level — not merely a statistically detectable one. For reference, the differential weight loss between the intensive lifestyle intervention arm and the standard care arm in the Look AHEAD trial was approximately 6–8% at one year, suggesting the pharmacologic gap between tirzepatide and semaglutide is in the same order of magnitude as an entire structured behavioral intervention program layered on top of standard care.
Cross-trial comparisons provide supporting consistency for the SURMOUNT-5 findings. In SURMOUNT-1 (NCT04184622, n=2,539), tirzepatide 15 mg/week produced a mean weight loss of 20.9% at 72 weeks in a non-diabetic obesity cohort (Jastreboff AM et al., NEJM 2022, PMID 35658024). In STEP 1 (NCT03548935, n=1,961), semaglutide 2.4 mg/week produced mean weight loss of 14.9% at 68 weeks (Wilding JPH et al., NEJM 2021, PMID 33567185). The close alignment — within approximately 1 percentage point in each case — between single-arm phase 3 data and SURMOUNT-5's head-to-head arms reduces concern that the observed advantage reflects a population sampling or protocol artifact rather than a true pharmacologic difference between agents.
Responder Analysis: Reaching Clinically Meaningful Weight-Loss Thresholds
Mean weight change is a useful summary statistic, but clinical decision-making frequently turns on threshold-based responder rates — the proportion of patients reaching ≥5%, ≥10%, ≥15%, ≥20%, or ≥25% body weight reduction. These benchmarks carry distinct clinical implications for metabolic risk factor resolution, hepatic steatosis regression, joint load reduction, and cardiometabolic endpoints across published subspecialty guidelines.
SURMOUNT-5 reported responder rates across these thresholds. The between-arm absolute difference widened progressively at higher thresholds:
- ≥5% body weight reduction: tirzepatide ~96%, semaglutide ~86% (absolute difference ~10 percentage points)
- ≥10% body weight reduction: tirzepatide ~87%, semaglutide ~72% (~15 percentage points)
- ≥15% body weight reduction: tirzepatide ~70%, semaglutide ~53% (~17 percentage points)
- ≥20% body weight reduction: tirzepatide ~51%, semaglutide ~33% (~18 percentage points)
- ≥25% body weight reduction: tirzepatide ~33%, semaglutide ~18% (~15 percentage points)
The progressive divergence at higher thresholds is the most clinically consequential pattern in the responder data. For patients where ≥20% weight reduction is a treatment target — candidates being evaluated for avoidance of bariatric surgery, those with metabolic-associated steatohepatitis (MASH) where histologic resolution requires substantial weight loss, or those pursuing aggressive cardiometabolic risk reduction — tirzepatide's advantage is proportionally larger than the mean-level difference alone suggests. Approximately half of tirzepatide-treated participants reached ≥20% weight loss versus approximately one-third of semaglutide-treated participants — a near-50% relative difference in high-threshold responder rates within the same trial design.
Mechanistic Basis for the Efficacy Gap Between Tirzepatide and Semaglutide
The receptor pharmacology underlying this efficacy difference is well-characterized at the molecular level. Semaglutide functions as a selective GLP-1 receptor agonist with high receptor affinity (EC50 approximately 0.03 nM in cell-based assays); its weight-reducing mechanisms center on hypothalamic appetite suppression via arcuate nucleus GLP-1R activation, delayed gastric emptying, and enhanced peripheral insulin sensitivity. Tirzepatide adds co-agonism at the glucose-dependent insulinotropic polypeptide (GIP) receptor — an incretin receptor expressed in adipocytes, central nervous system appetite circuits, and pancreatic β-cells, with signal transduction pathways mechanistically distinct from GLP-1R activation.
Preclinical modeling demonstrated that dual GIP/GLP-1 receptor co-agonism produces additive weight reduction beyond GLP-1 agonism alone in diet-induced obese rodent models, associated with both reduced caloric intake and measurable increases in energy expenditure (Willard FS et al., Sci Transl Med 2020, PMID 32493796). In adipocyte-focused studies, GIP receptor activation is associated with modulation of lipogenesis and fat oxidation, potentially contributing to favorable changes in fat depot composition beyond what GLP-1R activation achieves in isolation. The downstream signal transduction differences — including GIP receptor's distinct cAMP kinetics, β-arrestin recruitment profile, and differential central versus peripheral receptor distribution — provide a pharmacologic rationale for the observed SURMOUNT-5 efficacy gap that aligns with rather than contradicts preclinical mechanistic predictions.
Understanding how tirzepatide's dual GIP/GLP-1 receptor binding profile differs from selective GLP-1 agonism at the receptor and signaling level is essential context for interpreting why a 6.5 percentage point head-to-head weight loss advantage is consistent with — not surprising given — the underlying pharmacology.
Tolerability and Adverse Event Profile in SURMOUNT-5
Both agents share a class-associated adverse event profile dominated by GI effects — nausea, vomiting, diarrhea, and constipation — arising from GLP-1 receptor activation in the gut wall, dorsal vagal complex, and area postrema. In SURMOUNT-5, GI adverse events were reported in approximately 81% of tirzepatide-treated participants and 72% of semaglutide-treated participants. The majority of these events were mild-to-moderate in severity and concentrated during dose escalation phases, fully consistent with the class profile documented across prior pivotal trials for both agents.
Discontinuation due to adverse events was reported in approximately 6–8% of participants across both arms — numerically similar between groups, though the open-label design introduces potential differential ascertainment and reporting bias that limits precise comparison of tolerability metrics. Serious adverse event rates did not differ significantly between groups. No new safety signals beyond the established class profile for GLP-1 receptor agonists and GIP/GLP-1 dual agonists emerged from SURMOUNT-5 data.
Relevant contraindications applicable to both agents — personal or family history of medullary thyroid carcinoma, MEN2, and a history of pancreatitis — are detailed in each agent's current FDA-approved prescribing information. For a structured review of the GI, endocrine, and cardiovascular adverse event profiles across the GLP-1 receptor agonist class, including monitoring lab intervals and symptoms warranting clinician contact, consult each agent's current FDA-approved prescribing information.
What SURMOUNT-5 Does Not Answer
Applying head-to-head trial data accurately requires as much attention to what the trial did not measure as to what it did. Four limitations warrant explicit attention when translating SURMOUNT-5 findings to individual clinical contexts.
Type 2 diabetes populations. SURMOUNT-5 enrolled only adults without T2D. Both agents have extensive phase 3 datasets in diabetic populations — the SURPASS program for tirzepatide and the SUSTAIN program for semaglutide — but a controlled head-to-head weight loss comparison in T2D equivalent to SURMOUNT-5 in design rigor has not been published. The SURPASS-2 trial (NCT03987919) compared tirzepatide against semaglutide 1.0 mg/week (a sub-therapeutic dose for weight outcomes relative to Wegovy's 2.4 mg/week) in T2D and is not a direct analog to SURMOUNT-5's comparison arms.
Long-term durability post-discontinuation. SURMOUNT-5's 72-week window captures the on-treatment period but not the post-discontinuation trajectory. Separate maintenance and withdrawal trials — SURMOUNT-4 (NCT04660643) for tirzepatide and STEP 4 for semaglutide — demonstrate substantial weight regain for both agents after cessation, consistent with the chronic disease model of obesity pharmacotherapy. SURMOUNT-5 does not resolve whether tirzepatide's larger on-treatment reduction translates to a comparably larger absolute rebound, a different equilibrium point, or equivalent rebound kinetics.
Cardiovascular outcomes. Semaglutide has a positive MACE outcomes trial — SELECT (NCT03574597, n=17,604) — demonstrating a 20% relative risk reduction in major adverse cardiovascular events in high-CV-risk adults without T2D on optimized background therapy (Lincoff AM et al., NEJM 2023, PMID 37952131). Tirzepatide's dedicated MACE outcomes trial (SURMOUNT-MMO) was ongoing as of 2025. Weight-loss superiority in SURMOUNT-5 does not establish cardiovascular outcome equivalence with semaglutide, and this asymmetry in outcomes-level evidence is clinically relevant for high-CV-risk patient selection.
Body composition. SURMOUNT-5 did not include prespecified DXA-based body composition analysis as a primary or secondary endpoint. Whether tirzepatide's larger total weight reduction reflects proportionally greater fat mass loss, superior lean mass preservation, or differential fluid shifts requires dedicated substudy or independent RCT data. This gap is particularly relevant for older adults and patients with sarcopenic obesity, where lean mass preservation during weight loss carries independent functional and metabolic significance. A broader review of lean mass and fat mass outcomes across GLP-1 and dual agonist trials is an active area of post-marketing investigation.
Clinical Decision-Making in the Context of SURMOUNT-5 Data
The SURMOUNT-5 data supports a clear primary efficacy conclusion: tirzepatide produces statistically and clinically superior weight loss compared to semaglutide 2.4 mg/week over 72 weeks in adults with obesity or overweight without type 2 diabetes. Translating that conclusion into treatment selection requires integrating multiple patient-level and systems-level factors that the trial's primary endpoint alone does not resolve.
For patients with high established cardiovascular risk — specifically those meeting the SELECT trial's eligibility profile of prior MACE or high-risk atherosclerotic cardiovascular disease — semaglutide carries outcome-level evidence not yet replicated for tirzepatide in a comparable population. The SELECT data represent a different category of clinical evidence than weight-loss efficacy data; applying tirzepatide's SURMOUNT-5 weight advantage to MACE risk reduction in that population requires outcome-level data not yet available.
Prior GI tolerability history on semaglutide is a second relevant variable. Patients who experienced dose-limiting GI adverse events during semaglutide dose escalation are not assured a more favorable tolerability trajectory with tirzepatide; the GI adverse event rate in SURMOUNT-5's tirzepatide arm was numerically higher than in the semaglutide arm, not lower. However, titration to sub-maximum doses (5 mg or 10 mg tirzepatide/week) — which still exceeded semaglutide's weight loss performance in prior phase 3 data — may represent a clinically reasonable approach for tolerability-limited patients.
Formulary access, prior authorization criteria, and out-of-pocket cost structures for both agents differ substantially across US commercial, Medicare Part D, and employer-sponsored payers — and change frequently on annual formulary cycles. These real-world access constraints routinely drive prescribing decisions independently of efficacy data. A current review of GLP-1 receptor agonist payer dynamics, coverage criteria evolution, and prescribing access pathways is available through each plan's current formulary documentation.
Finally, dose optimization within the tirzepatide arm matters when interpreting SURMOUNT-5. Not all enrolled participants reached the 15 mg/week maximum dose; dose tolerability and escalation pace varied individually. Clinicians initiating tirzepatide should establish realistic expectations around the titration timeline — typically 20–32 weeks to maximum dose — and evaluate weight trajectory at intermediate doses (5 mg, 10 mg) before drawing conclusions about individual response.
SURMOUNT-5 Key Data Points: Reference Summary
- Trial: SURMOUNT-5, NCT05822609, Phase 3b open-label RCT, 72-week treatment period
- Population: n=751, BMI ≥30 or ≥27 + comorbidity, no T2D, baseline weight ~113 kg, baseline BMI ~40 kg/m²
- Tirzepatide (max 15 mg/week): mean weight loss −20.2%
- Semaglutide 2.4 mg/week: mean weight loss −13.7%
- Between-group difference: ~6.5 percentage points (95% CI ~−7.9 to −5.1), p < 0.001
- ≥25% weight loss responders: tirzepatide ~33% vs semaglutide ~18%
- GI adverse events: tirzepatide ~81% vs semaglutide ~72% (majority mild-moderate)
- Cardiovascular outcomes data: semaglutide has SELECT MACE trial data (PMID 37952131); tirzepatide MACE trial (SURMOUNT-MMO) ongoing as of 2025
- Publication: Jastreboff AM et al., N Engl J Med, 2025
For clinicians and researchers applying SURMOUNT-5 findings in practice, the appropriate starting point is the primary publication (Jastreboff AM et al., NEJM 2025) reviewed alongside each agent's current FDA-approved prescribing information — assessing individual patient contraindications, cardiovascular risk profile, GI tolerability history, and formulary access before any prescribing decision is reached.
This article summarizes research and does not constitute medical advice. Consult a licensed clinician for diagnosis, treatment, or any decisions about medications or supplements.